Boston Scientific (NYSE:BSX) Stock Unloaded by Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Boston Scientific stock on August 31st. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Boston Scientific Stock Down 0.8%

NYSE BSX traded down $0.36 on Tuesday, hitting $43.74. 14,539,899 shares of the company were exchanged, compared to its average volume of 18,790,520. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The company has a market cap of $63.40 billion, a PE ratio of 17.71, a PEG ratio of 1.05 and a beta of 0.57. The stock has a fifty day moving average of $46.98 and a 200-day moving average of $52.06. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $105.65.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 3.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on BSX shares. Robert W. Baird set a $56.00 target price on Boston Scientific in a report on Thursday, July 30th. Jefferies Financial Group dropped their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. UBS Group cut their price target on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, Raymond James Financial restated an “outperform” rating and issued a $57.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Twenty-three investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $70.19.

Hedge Funds Weigh In On Boston Scientific

Several hedge funds have recently made changes to their positions in BSX. Kingsview Wealth Management LLC boosted its position in Boston Scientific by 2.4% in the fourth quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider’s stock worth $578,000 after purchasing an additional 142 shares during the last quarter. Paragon Private Wealth Management LLC lifted its stake in shares of Boston Scientific by 1.2% in the 4th quarter. Paragon Private Wealth Management LLC now owns 15,950 shares of the medical equipment provider’s stock worth $1,521,000 after purchasing an additional 185 shares during the period. GraniteShares Advisors LLC boosted its holdings in shares of Boston Scientific by 1.5% in the first quarter. GraniteShares Advisors LLC now owns 13,599 shares of the medical equipment provider’s stock worth $853,000 after buying an additional 195 shares during the last quarter. Avantax Planning Partners Inc. grew its position in Boston Scientific by 4.0% during the first quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock valued at $329,000 after buying an additional 201 shares during the period. Finally, J.W. Cole Advisors Inc. raised its position in Boston Scientific by 2.4% in the fourth quarter. J.W. Cole Advisors Inc. now owns 8,768 shares of the medical equipment provider’s stock worth $836,000 after acquiring an additional 202 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Boston Scientific

In related news, Director David C. Habiger acquired 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney acquired 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 194,522 shares of company stock worth $9,385,210 in the last three months. Corporate insiders own 0.34% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.